A Narrative Review-Management of Malignant Pleural Effusion Related to Malignant Pleural Mesothelioma

Heart, Lung, & Circulation 2023 March 14 [Link] Maryum Qureshi, Bibhusal Thapa, Sanjeevan Muruganandan Abstract Malignant pleural mesothelioma (MPM) is an aggressive, almost universally fatal cancer with limited therapeutic options. Despite efforts, a real breakthrough in treatment and outcomes has been elusive. Pleural effusion with significant breathlessness and pain is the most typical presentation of…

Read More

TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy

Lung Cancer 2023 April [Link] Luca Hegedüs, Özlem Okumus, Fabian Mairinger, Till Ploenes, Sebastian Reuter, Martin Schuler, Anja Welt, Silvia Vega-Rubin-de-Celis, Dirk Theegarten, Agnes Bankfalvi, Clemens Aigner, Balazs Hegedüs Abstract Objectives: Malignant pleural mesothelioma (MPM) is an aggressive cancer which at large is not amenable to curative surgery. Despite the recent approval of immune checkpoint…

Read More

Mesothelioma In Situ Mimicking Well-differentiated Papillary Mesothelial Tumor

The American Journal of Surgical Pathology 2023 March 6 [Link] Francoise Galateau-Salle, Trevor Hamilton, Andrea MacNeill, Véronique Hofman, Ruth Sequeiros, Christine Sagan, Nolwenn Le Stang, Andrew Churg Abstract We have previously hypothesized that well-differentiated papillary mesothelial tumor (WDPMT) consists of 2 morphologically identical lesions, one of which is true WDPMT, while the other is a…

Read More

Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing

Lung Cancer 2023 April [Link] Hely Ollila-Raj, Astrid Murumägi, Teijo Pellinen, Mariliina Arjama, Eva Sutinen, Kirsi Volmonen, Heidi M Haikala, Olli Kallioniemi, Mikko I Mäyränpää, Ilkka Ilonen Abstract Objectives: Pleural mesothelioma (PM) is an aggressive malignancy with limited treatment options. The first-line therapy has remained unchanged for two decades and consists of pemetrexed in combination…

Read More

Defining and targeting tumor-associated macrophages in malignant mesothelioma

Proceedings of the National Academy of Sciences of the United States of America 2023 February 28 [Link] Licun Wu, Mikihiro Kohno, Junichi Murakami, Amin Zia, Jonathan Allen, Hana Yun, Meilin Chan, Cristina Baciu, Mingyao Liu, Veronique Serre-Beinier, Michele De Palma, Emanuela Felley-Bosco, Jonathan Yeung, Trevor J Pugh, Marc de Perrot Abstract Defining the ontogeny of…

Read More

The cytologic diagnosis of mesothelioma: are we there yet?

Journal of the American Society of Cytopathology 2022 December 26 [Link] Claire W Michael Abstract Introduction: Mesothelioma is a rare but highly aggressive malignancy with poor prognosis that frequently present with recurrent effusions. Establishing the diagnosis by cytology can lead to early diagnosis and treatment and consequently improve prognosis. Materials and methods: This review examines…

Read More

Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso)

BMJ Open 2022 November 10 [Link] Ruairi J H Conway, Jenny Symonds, Deborah Walton, Janet Probets, Charles Comins, Louise Stadon, John E Harvey, Kevin G Blyth, Nick A Maskell, Anna C Bibby Abstract Introduction: Mesothelioma is a heterogeneous disease that can be challenging to monitor and prognosticate. ASSESS-meso is a multicentre, prospective, longitudinal observational cohort…

Read More

Malignant Peritoneal Mesothelioma Features Shown by FDG-PET/CT

Cancer Diagnosis & Prognosis 2022 November 3 [Link] Kozo Kuribayashi, Kazuhiro Kitajima, Toshiyuki Minami, Masataka Ikeda, Koichiro Yamakado, Takashi Kijima Abstract Background/aim: Malignant peritoneal meso-thelioma (MPeM) has no specific imaging findings that can distinguish it from other peritoneal tumors and the accuracy of peritoneal cytology is low, therefore definitive diagnosis is usually performed by histology.…

Read More

The extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling

Frontiers in Oncology 2022 October 11 [Link] Arivazhagan Roshini, Chandra Goparaju, Somanath Kundu, Mohan S Nandhu, Sharon L Longo, John A Longo, Joan Chou, Frank A Middleton, Harvey I Pass, Mariano S Viapiano Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis and limited therapeutic options. The extracellular matrix protein fibulin-3/EFEMP1 accumulates…

Read More

Cytological Diagnosis of Malignant Mesothelioma: A Case Series

Journal of Cytology 2022 July-September [Link] Sakshi Dahiya, Meeta Singh, Shyama Jain, Bembem Khuraijam, Naman Suroya, Shramana Mandal Abstract Background: Mesotheliomas are neoplasms of the serosal lining of the body cavities. Diagnosis requires a multimodal approach of clinical findings, cytology, and histopathology with immunohistochemistry (IHC). The published sensitivity of cytology for diagnosing mesothelioma ranges from…

Read More